Physician profile
Matthew Glover
NPI 1760418594
$1,097.05
in general payments reported to CMS, 2019-2025
15 companies · $241 in 2025
The $241 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $209 · 2024: $399 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $640.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recor Medical INC | $336.57 | 2024-2025 | Paradise Renal Denervation System, Paradise Ultrasound Renal Denervation System |
| Boston Scientific Corporation | $158.96 | 2020-2025 | Watchman Access System, Watchman Flx |
| Impulse Dynamics (USA) INC. | $134.81 | 2024 | Optimizer |
| Covidien LP | $108.18 | 2019 | |
| Novartis Pharmaceuticals Corporation | $91.33 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.17 | 2019-2020 | |
| Medtronic Vascular, INC. | $36.64 | 2020 | |
| Calliditas Therapeutics US INC. | $34.54 | 2025 | Tarpeyo |
| Philips North America LLC | $29.27 | 2024 | (Ck4) Mcot |
| Fresenius USA Marketing, INC. | $25.96 | 2024 | Velphoro |
| Astellas Pharma US INC | $24.79 | 2019 | |
| One Lambda, INC. | $23.68 | 2025 | |
| Janssen Pharmaceuticals, INC | $23.15 | 2019-2020 | |
| Amgen INC. | $18.55 | 2024 | Repatha |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Glover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.